Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
Investment Firms›
Dcvc Bio
AddedFeb 13, 2024
UpdatedJul 3, 2026
Dcvc Bio

Dcvc Bio

Operating

VC fund, DCVC Bio, invests in early-stage computational biology startups transforming life sciences.

Location
Palo Alto, CA, US
Founded
2018
Firm
Compare
Portfolio
Employees
News
Website

DCVC Bio is a venture capital fund specializing in early-stage computational biology startups. The firm focuses on companies leveraging advances in genetic sequencing, artificial intelligence, and automation to transform life sciences technologies. Their investment interests span synthetic biology, medicine, and agriculture, with a particular emphasis on startups shaping the biochemical building blocks of the life sciences industry.

The fund's portfolio includes notable companies such as AbCellera Biologics, Chroma Medicine, and Pivot Bio. DCVC Bio has participated in numerous Series A rounds, as well as seed and Series B investments. The firm's approach combines deep technological expertise with a focus on startups poised to make significant impacts in their respective fields, supporting innovations that address critical challenges in healthcare, sustainability, and biotechnology.

Dcvc Bio - Portfolio Snapshot

Portfolio activity breakdown across disclosed investments and stages

Total Investments42
Current Portfolio Count23
Total Portfolio Exits0

Top Investment Stages

Series A23 (56.1%)
Seed8 (19.5%)
Series B8 (19.5%)
Convertible Note1 (2.4%)
Series C1 (2.4%)

Stage Mix

Series A 56%Seed 20%Series B 20%Convertible Note 2%Series C 2%

Concentration shown as share of disclosed investments by stage.

Recent Investments

Elo Life Systems logo

Elo Life Systems

Totus Medicines logo

Totus Medicines

CH4 Global logo

CH4 Global

Radionetics Oncology logo

Radionetics Oncology

Solu Therapeutics logo

Solu Therapeutics

Chroma Medicine logo

Chroma Medicine

Verdant Robotics logo

Verdant Robotics

Novome Biotechnologies logo

Novome Biotechnologies

Auron Therapeutics logo

Auron Therapeutics

Sabanto logo

Sabanto

Unlearn.AI logo

Unlearn.AI

Creyon Bio logo

Creyon Bio

Plexium logo

Plexium

GenEdit logo

GenEdit

Frontier Medicines logo

Frontier Medicines

Stemson Therapeutics logo

Stemson Therapeutics

Umoja Biopharma logo

Umoja Biopharma

MycoWorks logo

MycoWorks

Orca Bio logo

Orca Bio

AbCellera Biologics logo

AbCellera Biologics

Empirico logo

Empirico

X-37 logo

X-37

Macromoltek logo

Macromoltek

Dcvc Bio - Similar Investment Firms

Dcvc logo

Dcvc

dcvc.com

DCM logo

DCM

dcm.com

Bioluminescence Ventures logo

Bioluminescence Ventures

DVC logo

DVC

joindvc.com

Dhvc logo

Dhvc

dh.vc

Two Sigma Ventures logo

Two Sigma Ventures

Vida Ventures logo

Vida Ventures

vidaventures.com

Nest.Bio Venture logo

Nest.Bio Venture

nest.bio

Deutsche Venture Capital logo

Deutsche Venture Capital

8VC logo

8VC

8vc.com

Atlas Venture logo

Atlas Venture

atlasventure.com

Foresite Capital logo

Foresite Capital

Versant Ventures logo

Versant Ventures

Endpoint Ventures logo

Endpoint Ventures

endpoint.vc

Dallas Venture Capital logo

Dallas Venture Capital

dallasvc.com

Dcvc Bio - Classification

Also Known As
  • Dcvc Bio LLC Management
NAICS
  • 520000Finance and Insurance
  • 523000Securities, Commodity Contracts, and Other Financial Investments and Related Activities
  • 523900Other Financial Investment Activities
  • 523990All Other Financial Investment Activities
  • 523999Miscellaneous Financial Investment Activities
SIC
  • 6700Holding And Other Investment Offices
  • 6790Miscellaneous Investing
  • 6799Investors, Not Elsewhere Classified
Show 6 more industry codes
NAICS
  • 525000Funds, Trusts, and Other Financial Vehicles
  • 523910Miscellaneous Intermediation
  • 523940Portfolio Management and Investment Advice
SIC
  • 6000Depository Institutions
  • 6720Investment Offices
  • 6722Management Investment Offices, Open-end